Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
October 02, 2023 01:15 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Phase III APPLAUSE-IgAN study met its pre-specified interim analysis primary endpoint, demonstrating superiority of iptacopan vs placebo in proteinuria...
Novartis completes divestment of ‘front of eye’ ophthalmology assets
September 29, 2023 10:00 ET
|
Novartis Pharma AG
Divestment includes Xiidra®, on-market treatment for dry eye disease and additional ophthalmic investigational therapiesNovartis advances strategy of focused portfolio and prioritized therapeutic...
Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe
September 26, 2023 01:15 ET
|
Novartis Pharma AG
Biosimilar Tyruko® approved for all indications of reference medicine, as first and only biosimilar to treat relapsing forms of multiple sclerosis (MS) in EuropeDecision based on evidence from...
Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
September 25, 2023 01:17 ET
|
Novartis Pharma AG
Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (ORR) in patients with Grade 2 and 3 advanced...
Novartis confirms Sandoz Spin-off for October 4, 2023
September 25, 2023 01:15 ET
|
Novartis Pharma AG
Sandoz shares (SDZ) to be listed and traded on SIX Swiss Exchange; ADRs to be traded on OTCQX®, first trading day October 4, 2023Sandoz to be included in key Swiss market indicesInvestment grade...
Aktionärinnen und Aktionäre von Novartis stimmen dem geplanten 100% igen Spin-off von Sandoz zu
September 15, 2023 05:36 ET
|
Novartis Pharma AG
Die Aktionärinnen und Aktionäre stimmen dem geplanten 100%igen Spin-off von Sandoz, dem Generika- und Biosimilars-Geschäft von Novartis, zu.Die Aktionärinnen und Aktionäre stimmen ausserdem einer...
Les actionnaires de Novartis approuvent le projet de scission à 100% de Sandoz
September 15, 2023 05:36 ET
|
Novartis Pharma AG
Les actionnaires approuvent le projet de scission à 100% de Sandoz, l’activité Génériques et Biosimilaires de NovartisLes actionnaires approuvent également une réduction du capital social dans le...
Novartis shareholders approve the proposed 100% Spin-off of Sandoz
September 15, 2023 05:36 ET
|
Novartis Pharma AG
Shareholders approve the proposed 100% Spin-off of Sandoz, the Generics and Biosimilars business of NovartisShareholders also approve a reduction of share capital in connection with the Spin-off...
Sandoz announces exclusive deal to commercialize biosimilar ustekinumab, further reinforcing growing pipeline and immunology patient offering
September 11, 2023 01:15 ET
|
Novartis Pharma AG
Agreement with Samsung Bioepis gives Sandoz exclusive commercialization rights to biosimilar SB17 ustekinumab in Europe and North AmericaUstekinumab is a fully human monoclonal antibody to interleukin...
Novartis appoints Patrick Horber, M.D., President, International as Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, steps down from the Executive Committee of Novartis
September 06, 2023 01:15 ET
|
Novartis Pharma AG
After nearly seven years at Novartis and more than four years as a member of the ECN, Ms. Tschudin will pursue her next chapter of leadership outside of Novartis Dr. Horber to drive next phase...